Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks.

Expert review of clinical pharmacology - 1 Jan 2000

Bentley Siân, Cheong Jamie, Gudka Nikesh, Makhecha Sukeshi, Hadjisymeou-Andreou Simone, Standing Joseph F

Abstract excerpt

INTRODUCTION: Medicine use in children with cystic fibrosis (CF) is complicated by inconsistent pharmacokinetics at variance with the general population, a lack of research into this and its effects on clinical outcomes. In the absence of established dose regimens, therapeutic drug monitoring (TDM) is a clinically relevant tool to optimize drug exposure and maximize therapeutic effect by the bedside. In clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Monitoring

Share to Mutation

Source

Identifiers

PMID: 37470695
DOI: 10.1080/17512433.2023.2238597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks.PMID 37470695Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Multimatrix Monitoring of CFTR Modulators Reflecting Systemic Exposure, Airway Targeting, and Sweat Compartment in People with Cystic FibrosisSemantic proximity Read ↗

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.Semantic proximity Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®.Semantic proximity Read ↗

Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.Semantic proximity Read ↗

Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.Semantic proximity Read ↗

Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.Semantic proximity Read ↗

Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review.Semantic proximity Read ↗

A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic MonitoringSemantic proximity Read ↗

Genotype Informed Bayesian Dosing of Tacrolimus in Paediatric Solid Organ Transplant IndividualsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.